drugset / Trial / NCT07661030
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time
Phase 4
Not yet recruiting
142 enrolled
First Affiliated Hospital of Wenzhou Medical University
The Affiliated People's Hospital of Ningbo University · collabWenzhou Central Hospital · collabYuyao People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients.
Timeline
- Start
- 2026-07-30
- Primary completion
- 2027-07-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dotinurad | Small molecule | 2 mg | — |
| Background | Colchicine | Small molecule | 1 mg | — |
| Background | Etoricoxib | Small molecule | 60 mg | — |